2933.99.01 | 00 | Butyl (R)-2-[4-(5-trifluoromethyl-2- pyridinyloxy)phenoxy]propanoate | kg | Free | | 15.4¢/kg + 50% |
2933.99.02 | 00 | 2-[4-[(6-Chloro-2-quinoxalinyl)oxy]phenoxy]- propionic acid, ethyl ester; and O,O-Dimethyl-S-[(4-oxo-1,2,3-benzotri- azin-3-(4H)-yl)methyl]phosphorodithioate | kg | Free | | 15.4¢/kg + 64.5% |
2933.99.08 | 00 | Acetoacetyl-5-aminobenzimidazolone; 3-(2H-Benzotriazol-2-yl)-5-(tert-butyl)-4- hydroxybenzene propanoic acid, C7-C9 branched or linear alkyl esters; 2-(2H-Benzotriazol-2-yl)-6-dodecyl-4- methyl phenol, in liquid form, branched and linear; and 1,3,3-Trimethyl-2-methyleneindoline | kg | Free | | 15.4¢/kg + 52% |
2933.99.12 | 00 | 6-Bromo-5-methyl-1H-imidazo[4,5-b]- pyridine; 2-sec-Butyl-4-tert-butyl-6-(benzotriazol-2- yl)phenol; 2-tert-Butyl-4-methyl-6-(5-chlorobenzotri- azol-2-yl)phenol; 2,4-Di-tert-butyl-6-(benzotriazol-2-yl)phenol; 2,4-Di-tert-butyl-6-(5-chlorobenzotriazol-2- yl)phenol; 2,3-Dichloro-6-quinoxalinecarbonyl chloride; 1-Hydroxy-2-carbazolecarboxylic acid; 2-Hydroxy-3-carbazolecarboxylic acid; 2-Hydroxy-3-carbazolecarboxylic acid, sodium salt; Iminodibenzyl(10,11-dihydro-5H-dibenz- [b,f]azepine); Indoline; 3-Methylbenzo[f]quinoline; 2-Methylindoline; 2-Methylmercaptobenzimidazole; 1-Methyl-2-phenylindole; 1-Methylpyrazine; 2,4-Methylpyrazolic acid; 2-Phenylbenzimidazole; 2-Phenylindole; Tetramethylpyrazine; 2,3,5-Triphenyltetrazolium chloride; dl-Tryptophan; and Vinylcarbazole, monomer | kg | 5.8% | Free (A+,AU,BH, CA,CL,D,E,IL,J, JO,K,MA,MX, P,SG) | 15.4¢/kg + 39.5% |
2933.99.55 | 20 | Tolmetin sodium dihydrate | kg | | | |
2933.99.55 | | Drugs primarily affecting the central nervous system: | | | | |
2933.99.79 | 00 | Products described in additional U.S. note 3 to section VI | kg | 6.5% | Free (A+,AU,BH, CA,CL,D,E,IL,J, JO,K,L,MA,MX, P) 2.9% (SG) | 15.4¢/kg + 52% |
2933.99.87 | 00 | Hexamethylenetetramine | kg | 6.3% | Free (A,AU,BH,CA, CL,E,IL,J,JO, MA,MX, P,SG) | 58% |
2934 | | Nucleic acids and their salts, whether or not chemically defined; other heterocyclic compounds: | | | | |
2934.10 | | Compounds containing an unfused thiazole ring (whether or not hydrogenated) in the structure: | | | | |
2934.10.10 | 00 | Products described in additional U.S. note 3 to section VI | kg | 6.5% | Free (A+,AU,BH, CA,CL,D,E,IL,J, JO,K,MA,MX, P) 2.9% (SG) | 15.4¢/kg + 52% |
2934.10.70 | 00 | 4,5-Dichloro-2-n-octyl-4-isothiazolin-3-one; Ethyl 2-(2-aminothiazol-4-yl)-2- hydroxyiminoacetate; Ethyl 2-(2-aminothiazol-4-yl)-2- methoxyiminoacetate; 2-Methyl-4-isothiazolin- 3-one; 2-n-Octyl-4-isothiazolin-3-one; and Thiothiamine hydrochloride | kg | Free | | 30.5% |
2934.20 | | Compounds containing in the structure a benzothiazole ring-system (whether or not hydrogenated), not further fused: | | | | |
2934.20.05 | 00 | N-tert-Butyl-2-benzothiazolesulfenamide | kg | 6.5% | Free (A,AU,BH,CA, CL,E,IL,J,JO, MA,MX,P) 0.2¢/kg + 3.1% (SG) | 15.4¢/kg + 52% |
2934.20.40 | 00 | Products described in additional U.S. note 3 to section VI | kg | 6.5% | Free (A+,AU,BH, CA,CL,D,E,IL,J, JO,K,L,MA,MX, P) 2.9% (SG) | 15.4¢/kg + 52% |
2934.30 | | Compounds containing in the structure a phenothiazine ring-system (whether or not hydrogenated), not further fused: | | | | |
2934.30.18 | 00 | Ethyl (1H-phenothiazin-2,4,1)carbamate | kg | Free | | 15.4¢/kg + 52% |
2934.30.43 | 00 | Products described in additional U.S. note 3 to section VI | kg | 6.5% | Free (A+,AU,BH, CA,CL,D,E,IL,J, JO,K,MA,MX, P) 2.9% (SG) | 15.4¢/kg + 52% |
2934.99.01 | 00 | Mycophenolate mofetil | kg | Free | | 15.4¢/kg + 45% |
2934.99.03 | 00 | 2-Acetylbenzo(b)thiophene; 3-Methylene-7-(2-phenoxyacetamido)- cephan-4-carboxylic acid, p-nitrobenzyl ester, 1-oxide; and Naphth[1,2-d]-[1,2,3]-oxadiazole-5-sulfonic acid and its sodium salt | kg | Free | | 15.4¢/kg + 52% |
2934.99.07 | 00 | Ethyl 2-[4-[(6-chloro-2-benzoxazolyl)oxy]- phenoxy]propanoate (Fenoxaprop-ethyl) | kg | Free | | 15.4¢/kg + 48.5% |
2934.99.11 | 00 | 2-tert-Butyl-4-(2,4-dichloro-5- isopropoxyphenyl)- 2-1,3,4- oxadiazolin-5-one; 3-Isopropyl-1H-2,1,3- benzothiadiazin-4-(3H)-one-2,2- dioxide (Bentazon); and O,O-Diethyl-S-[(6-chloro-2- oxobenzoxazolin-3-yl)methyl]¢/phosphorodithioate (Phosalone) | kg | 6.5% | Free (A,AU,BH,CA, CL,E,IL,J,JO, MA,MX, P,SG) | 15.4¢/kg + 40.5% |
2934.99.39 | 00 | Products described in additional U.S. note 3 to section VI | kg | 6.5% | Free (A+,AU,BH, CA,CL,D,E,IL,J, JO,K,L,MA,MX, P) 2.9% (SG) | 15.4¢/kg + 52% |
2935.00.06 | 00 | 4-Amino-6-chloro-m-benzenedisulfonamide; and Methyl-4-aminobenzenesulfonylcarbamate (Asulam) | kg | 6.5% | Free (A,AU,BH,CA, CL,E,IL,J,JO, K,MA,MX, P,SG) | 15.4¢/kg + 41% |
2935.00.13 | 00 | (5-[2-Chloro-4-(trifluoromethyl)phenoxy]-¢/(methylsulfonyl)-2-nitrobenzamide) (Fomesafen); N-(2,6-Dichloro-3-methylphenyl)-5-amino-1,3,4- triazole-2-sulfonamide; 2,4-Dichloro-5-sulfamoylbenzoic acid; N-Ethyl-o-toluenesulfonamide; N-Ethyl-p-toluenesulfonamide; 7-(Hexadecylsulfonylamino)-1H-indole; Methyl 5-{[(4,6-dimethoxy-2-pyrimidinyl)amino]- carbonylaminosulfonyl}-3-chloro-1-methyl-1H- pyrazole-4-carboxylate (Halosulfuron methyl); and Mixtures of ortho- and para-toluene sulfonamides | kg | Free | | 15.4¢/kg + 57.5% |